Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes JOHNB. B USE,MD, PHD1 ROBERT R. H ENRY,MD2 JENNY HAN,MS3 DENNIS D. K IM,MD3MARKS. F INEMAN ,BS3 ALAIND. B ARON,MD3 FOR THE EXENATIDE -113 C LINICAL STUDY GROUP* OBJECTIVE — This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses ofa sulfonylurea as monotherapy. RESEARCH DESIGN AND METHODS — This was a triple-blind, placebo-controlled, 30-week study conducted at 101 sites in the U.S. After a 4-week, single-blind, placebo lead-inperiod, 377 subjects were randomized (60% men, age 55 /H1100611 years, BMI 33 /H110066 kg/m 2, HbA1c 8.6/H110061.2% [/H11006SD]) and began 4 weeks at 5 /H9262g subcutaneous exenatide twice daily (before